Clinical Trial

Alnuctamab for Refractory SLE (LATTE Study)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-10-20; most recent amendment 2026-04-16.
Status change: Not Yet Recruiting → Recruiting 2025-12-15
Trial Details
NCT Number NCT07219563
Lead Sponsor Icahn School of Medicine at Mount Sinai
Conditions Systemic Lupus Erythematosus
Enrollment 21 participants
Start Date 2026-03-17
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-21